Home > Insider Trading > Filing (0001140361-23-004735)

Filing Details

Accession Number:: 0001140361-23-004735
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-06 17:45:21
Reporting Period:: 2023-02-02

Accepted Time:: 2023-02-06 17:45:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1746473	Pliant Therapeutics Inc.	PLRX	Pharmaceutical Preparations (2834)	474272481

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808895	Bernard Coulie	C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-02-02	15,000	$6.22	255,112	No	4	M	Direct
Common Stock	Disposition	2023-02-02	13,395	$34.13	241,717	No	4	S	Direct
Common Stock	Disposition	2023-02-02	1,605	$34.96	240,112	No	4	S	Direct
Common Stock	Acquisiton	2023-02-03	15,000	$6.22	255,112	No	4	M	Direct
Common Stock	Disposition	2023-02-03	9,738	$33.36	245,374	No	4	S	Direct
Common Stock	Disposition	2023-02-03	5,262	$34.08	240,112	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-02-02	15,000	$0.00	15,000	$6.22
Common Stock	Stock Option (right to buy)	Disposition	2023-02-03	15,000	$0.00	15,000	$6.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
342,262		2030-03-30	No	4	M	Direct
327,262		2030-03-30	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	409,317	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.48, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.83, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.